Literature DB >> 2482031

CD5+ B lymphocytes, polyreactive antibodies and the human B-cell repertoire.

P Casali, A L Notkins.   

Abstract

The lock and key model of antigen-antibody reaction has traditionally been used to explain the specificity of antibodies and the need for antibody diversity. Recently it has become clear that certain antibodies are polyreactive and recognize a variety of self- and foreign antigens. It is now clear that these antibodies are made by a novel subset of B cells that bear the surface CD5 marker. Careful analysis has shown that about 20% of peripheral blood B lymphocytes in adults are CD5+ and, therefore, represent a major component of the normal human B-cell repertoire. The precise role of the antibodies produced by these cells is still not clear, but because of their polyreactivity they might function in clearing autoantigens from the circulation and/or as a rapid first line of defense against foreign invaders, such as bacteria and viruses. Sequence analysis showed that these antibodies use gene segments in germ-line configuration for their antigen-binding portion. In this article, Paolo Casali and Abner Notkins propose that polyreactive antibodies are what, for years, have been referred to as the 'natural antibodies' of serum and that under certain circumstances they may contribute to the pathogenesis of autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2482031     DOI: 10.1016/0167-5699(89)90268-5

Source DB:  PubMed          Journal:  Immunol Today        ISSN: 0167-5699


  99 in total

Review 1.  The role of complement in the acquired immune response.

Authors:  C H Nielsen; E M Fischer; R G Leslie
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

2.  Immunochemical properties of anti-Gal alpha 1-3Gal antibodies after sensitization with xenogeneic tissues.

Authors:  P B Yu; W Parker; M L Everett; I J Fox; J L Platt
Journal:  J Clin Immunol       Date:  1999-03       Impact factor: 8.317

3.  Natural antibodies in childhood: development, individual stability, and injury effect indicate a contribution to immune memory.

Authors:  P Mirilas; C Fesel; B Guilbert; N G Beratis; S Avrameas
Journal:  J Clin Immunol       Date:  1999-03       Impact factor: 8.317

4.  Increased transforming growth factor-beta (TGF-beta)-secreting T cells and IgA anti-cardiolipin antibody levels during acute stage of childhood Henoch-Schönlein purpura.

Authors:  Y H Yang; M T Huang; S C Lin; Y T Lin; M J Tsai; B L Chiang
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

5.  Analysis of lymphocyte phenotypes in cord blood from early gestation fetuses.

Authors:  M Peakman; A G Buggins; K H Nicolaides; D M Layton; D Vergani
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

Review 6.  Polyreactive antibodies in adaptive immune responses to viruses.

Authors:  Hugo Mouquet; Michel C Nussenzweig
Journal:  Cell Mol Life Sci       Date:  2011-11-02       Impact factor: 9.261

Review 7.  Autoantibodies and antibacterial antibodies: from both sides now.

Authors:  R A Watts; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1990-12       Impact factor: 19.103

8.  Pathogenic anti-DNA idiotype-reactive IgG in intravenous immunoglobulin preparations.

Authors:  F Silvestris; P Cafforio; F Dammacco
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

9.  Intraperitoneal immunization of human subjects with tetanus toxoid induces specific antibody-secreting cells in the peritoneal cavity and in the circulation, but fails to elicit a secretory IgA response.

Authors:  C Lue; A W van den Wall Bake; S J Prince; B A Julian; M L Tseng; J Radl; C O Elson; J Mestecky
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

10.  Natural human antibodies to pneumococcus have distinctive molecular characteristics and protect against pneumococcal disease.

Authors:  H E Baxendale; M Johnson; R C M Stephens; J Yuste; N Klein; J S Brown; D Goldblatt
Journal:  Clin Exp Immunol       Date:  2007-11-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.